LadRx Corp

LADXD.PK

$

Closing

1D

YTD

LADX

No FIGI found

Market cap

$

52 week high

$

52 week low

$

Volume

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

Revenue Growth (Annual)

0.00%

52 week high

$

52 week low

$

Div. Yield

%

EPS Annual Growth

102.94

Company Profile

LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s LADR (Linker Activated Drug Release) technology platform consists of an organic backbone that is attached to a chemotoxic agent. The LADR backbone is to target and deliver the chemotoxic agent to the tumor environment and then to release the chemotoxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADR7, 8, 9, and 10, combine the proprietary LADR backbone with novel derivatives of the auristatin and maytansinoid drug classes.